LIXT News & Events

LIXTE Biotechnology has appointed Sidney Braun as CEO of the Company's Liora Technologies Europe Ltd. subsidiary. A veteran of the healthcare industry, Braun brings to Liora more than two decades of operational and strategic advisory experience at companies in North America, Europe and Israel. He was instrumental in the creation of Liora and facilitated LIXTE's acquisition of Liora's assets in November 2025 from Orbit Capital, Inc.

LIXTE Biotechnology engaged IBN to assist with its corporate communications strategy. As part of the client-partner relationship, IBN will leverage its investor-focused distribution network, which includes over 5,000 key syndication outlets, various newsletters, social media channels, and wire services via InvestorWire, along with blogs and other outreach tools, to generate greater awareness for LIXTE Biotechnology.

LIXTE Biotechnology announced it is expanding its collaboration with The University of Texas MD Anderson Cancer Center and pharmaceutical manufacturer GSK on an ongoing clinical trial with LIXTE's proprietary compound, LB-100, to treat ovarian clear cell cancer. The trial, which combines LB-100 with GSK's Dostarlimab to enhance the effectiveness of immunotherapy, was initiated in January 2024. A second trial site was added earlier this year at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. MD Anderson and Northwestern Medical Center plan to double the number of enrollments in the trial to 42 patients, after successfully attaining its initial target of 21 patients earlier this year. The Company also announced that it expects data to be presented from the trial on the initial 21 patients in the first half of 2026.

Lixte Biotechnology entered into definitive agreements in a registered direct offering with accredited investors for the purchase and sale of approximately $4.3M of shares of Common Stock and pre-funded and investor warrants at a price of $4.09 per Common Unit. The entire transaction has been priced at the market under Nasdaq rules. The offering consisted of the sale of 1,051,342 Common Units, each consisting of one share of Common Stock or one Pre-Funded Warrant and one Common Warrant to purchase one share of Common Stock per warrant at an exercise price of $3.96. The public offering price per Common Unit is $4.09. The Pre-Funded Warrants will be immediately exercisable and may be exercised at any time until exercised in full. For each Pre-Funded Unit sold in the offering, the number of Common Units in the offering will be decreased on a one-for-one basis. The initial exercise price of each Common Warrant is $3.96 per share of Common Stock. The Common Warrants are exercisable immediately and expire 60 months after the initial issuance date. Aggregate gross proceeds to the Company are expected to be approximately $4.3less than. The transaction is expected to close on or about December 19, subject to the satisfaction of customary closing conditions. The Company expects to use the net proceeds from the offering, together with its existing cash, for general corporate purposes and working capital. Spartan Capital Securities, is acting as exclusive placement agent for the offering.